As a public health professional, I want people to have access to the health care they need to improve their quality of life. For years I researched available treatments for specific illnesses to determine their safety and efficacy, growing to become an advocate for the development of new treatments for those living with rare diseases.
Yet, for too long, I had no idea the Food and Drug Administration convenes groups of experts, known as advisory committees or ad comms, to review trial data for treatments and make recommendations to inform the FDA’s regulatory decision-making. There are 50 technical and scientific ad comms, made up of more than 200 people, across the FDA. They review the safety and efficacy of medical products.
Even if members of the public don’t know about ad comms, they depend on these expert recommendations, which heavily influence the FDA’s final decision to approve or reject a new treatment.
Click this link for the original source of this article.
Author: Cheri Banks
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
